Skip to content
Attention! Product verification is temporarily unavailable.

· 1 min read

Hilma Biocare Introduces new products – Tirzepatide and Retatrutide.

Hilma Biocare Introduces new products – Tirzepatide and Retatrutide.

Hilma Biocare introduces new products – Tirzepatide and Retatrutide. These innovative medications are designed to treat type 2 diabetes and promote weight loss in obesity. Tirzepatide is a dual-action drug: a GLP-1 and GIP receptor agonist. Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors. These medications suppress appetite and accelerate metabolism, resulting in weight loss.

All news
Share

More Hilma Biocare news

All news

The new line of peptides has been added to the range: these are well-known and innovative preparations from the field of cellular and mitochondrial medicine, now known as “biohacking.” These preparations demonstrate broad potential in…

Read

Optimized packaging

Optimized packaging means saving nature. Hilma Biocare introduces new compact packaging for pre-filled pens. The new packaging requires fewer materials, which is better for the environment. During the transition period, pens will be…

Read

Want to be Hilma Biocare products Reseller?

Please contact our manager to discuss collaboration details directly via Message form.